Riskpilot← Back to searchSign inGet full accessBIOlabb Dalarna AB
ABIn liquidationOrg 5590583091Technical testing and analysis · NACE 7120Est. 20160 employees
Revenue 2024
SEK 89K
-21% vs 2023
EBITDA margin
83.1%
+1750% vs 2023
Equity ratio
59.7%
Financial strength
Net profit 2024
SEK 74K
+1025% vs 2023
| Revenue | SEK 89K | -21% |
| EBITDA | SEK 74K | +1750% |
| Net profit | SEK 74K | +1025% |
| Total assets | SEK 305K | +43% |
| Equity | SEK 182K | +67% |
| Employees | 0 | — |
Legal name
BIOlabb Dalarna AB
Org number
5590583091
Legal form
Aktiebolag
NACE code
7120 · Technical testing and analysis
Founded
11 april 2016
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-03-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av likvidatorn externa firmatecknarna
Company purpose
Föremålet för bolagets verksamhet är att bedriva foderanalyser, livsmedelsanalyser, radonmätningar, andra mikrobiologiska och kemiska/fysiska undersökningar av både vatten och livsmedel samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 88 | 64 | 172 | 112 | 89 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −42 | −13 | 103 | 4 | 74 |
| Depreciation & amort. | −80 | −12 | −12 | −12 | −0 |
| EBIT | −122 | −25 | 91 | −8 | 74 |
| Net financials | — | — | — | — | — |
| Profit before tax | −122 | −25 | 91 | −8 | 74 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −122 | −25 | 91 | −8 | 74 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 159 | 130 | 243 | 214 | 305 |
| Equity | 26 | 26 | 117 | 109 | 182 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 133 | 104 | 126 | 105 | 122 |
| Total debt | 133 | 104 | 126 | 105 | 122 |
EBITDA margin
83.1%
This company
15.8%
Market median
+426% vs market
20202024
Equity ratio
59.7%
This company
38.2%
Market median
+56% vs market
20202024
Return on equity
40.7%
This company
18.4%
Market median
+121% vs market
20202024
Net profit margin
83.1%
This company
8.1%
Market median
+926% vs market
20202024
Asset turnover
0.29×
This company
1.12×
Market median
-74% vs market
20202024
Debt / equity
0.68×
This company
0.62×
Market median
+10% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-04-01 – 2022-03-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-04-01 – 2021-03-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-04-01 – 2020-03-31
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
LB External Signatory | External Signatory | 2024 |
IM Liquidator | Liquidator | 2024 |
BJ External Signatory | External Signatory | 2024 |
UM External Signatory | External Signatory | 2024 |
| Former (2) | ||
BL Chief Executive Officer | Chief Executive Officer | 2022 – 2024 |
KM Audit | Audit | 2022 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
| Board of Directors | 2022 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BIOlabb Dalarna AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lena Birgitta Killgren Jonsson | External Signatory | 0 companies |
| Inger Margareta Dahle | Liquidator | 0 companies |
| Bengt Junior Niklas Nygårds | External Signatory | 0 companies |
| Bart Lucien Vervust | Chief Executive Officer | 0 companies |
| Ulrika Margareta Ahlholm | External Signatory | 0 companies |
| Karin Majvor Leksell | Audit | 0 companies |
| Jessica Vroonen | Board of Directors | 0 companies |